News & Media > Letter from Janssen to BHIVA re: Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2

Letter from Janssen to BHIVA re: Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2

Monday 16 March 2020

Download the letter received from Janssen Pharmaceutical Companies of Johnson & Johnson



For further information, please contact Jo Josh on +44 (0) 7787 530922 or jo@commsbiz.com